Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(50.0%)
N/A
1(50.0%)
2Total
Phase 3(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03235193Not ApplicableCompleted

Predictive algoRithm for EValuation and Intervention in SEpsis

Role: collaborator

NCT01570855Completed

Chemotherapy Resistance and Sensitivity Testing in Lung Tumors

Role: collaborator

NCT00802477Phase 3Unknown

Application Of Autologous Blood Products During Modified Radical Mastectomy

Role: collaborator

All 3 trials loaded